288 related articles for article (PubMed ID: 30645008)
1. Tamoxifen induces toxicity, causes autophagy, and partially reverses dexamethasone resistance in Jurkat T cells.
Torres-López L; Maycotte P; Liñán-Rico A; Liñán-Rico L; Donis-Maturano L; Delgado-Enciso I; Meza-Robles C; Vásquez-Jiménez C; Hernández-Cruz A; Dobrovinskaya O
J Leukoc Biol; 2019 May; 105(5):983-998. PubMed ID: 30645008
[TBL] [Abstract][Full Text] [Related]
2. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells.
Liu L; Liu S; Luo H; Chen C; Zhang X; He L; Tu G
Aging (Albany NY); 2021 Jun; 13(12):16178-16197. PubMed ID: 34182538
[TBL] [Abstract][Full Text] [Related]
3. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.
Pons DG; Torrens-Mas M; Nadal-Serrano M; Sastre-Serra J; Roca P; Oliver J
Int J Biochem Cell Biol; 2015 Sep; 66():85-94. PubMed ID: 26232188
[TBL] [Abstract][Full Text] [Related]
4. Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1.
Wang Y; Qu Y; Zhang XL; Xing J; Niu XL; Chen X; Li ZM
Mol Cell Endocrinol; 2014 Feb; 382(2):791-803. PubMed ID: 24189439
[TBL] [Abstract][Full Text] [Related]
5. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
6. Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
Zekas E; Prossnitz ER
BMC Cancer; 2015 Oct; 15():702. PubMed ID: 26470790
[TBL] [Abstract][Full Text] [Related]
7. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells.
Qu C; Ma J; Zhang Y; Han C; Huang L; Shen L; Li H; Wang X; Liu J; Zou W
Cancer Sci; 2019 Jan; 110(1):221-234. PubMed ID: 30417588
[TBL] [Abstract][Full Text] [Related]
9. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen induces the expression of maspin through estrogen receptor-alpha.
Liu Z; Shi HY; Nawaz Z; Zhang M
Cancer Lett; 2004 Jun; 209(1):55-65. PubMed ID: 15145521
[TBL] [Abstract][Full Text] [Related]
12. The G-protein-coupled estrogen receptor, a gene co-expressed with ERα in breast tumors, is regulated by estrogen-ERα signalling in ERα positive breast cancer cells.
Pal U; Manjegowda MC; Singh N; Saikia S; Philip BS; Jyoti Kalita D; Kumar Rai A; Sarma A; Raphael V; Modi D; Chandra Kataki A; Mukund Limaye A
Gene; 2023 Aug; 877():147548. PubMed ID: 37279863
[TBL] [Abstract][Full Text] [Related]
13. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
[TBL] [Abstract][Full Text] [Related]
14. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM
Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
[TBL] [Abstract][Full Text] [Related]
16. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
Li Y; Birnbaumer L; Teng CT
Mol Endocrinol; 2010 May; 24(5):969-80. PubMed ID: 20211987
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
[TBL] [Abstract][Full Text] [Related]
18. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
